Trials / Completed
CompletedNCT04133116
A Study of LY3471851 in Healthy Participants
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3471851 in Japanese and Caucasian Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Nektar Therapeutics · Industry
- Sex
- All
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to explore the safety and tolerability of LY3471851 in healthy Japanese and Caucasian participants. The study will also estimate how much LY3471851 gets into the blood stream and how long it takes the body to remove it. The study is expected to last about 7 weeks for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3471851 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2019-10-29
- Primary completion
- 2020-03-06
- Completion
- 2020-03-06
- First posted
- 2019-10-21
- Last updated
- 2023-11-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04133116. Inclusion in this directory is not an endorsement.